<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851797</url>
  </required_header>
  <id_info>
    <org_study_id>EPYDIS (DSC/14/2357/48)</org_study_id>
    <nct_id>NCT02851797</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      it is a randomised, double blind, parallel group, placebo controlled study. A total of 179&#xD;
      male ambulant subjects will be randomised 2:1 (givinostat:placebo).&#xD;
&#xD;
      Subjects will be stratified for their concomitant use of steroids in 4 strata:&#xD;
&#xD;
        1. Deflazacort daily regimen&#xD;
&#xD;
        2. Deflazacort intermittent regimen&#xD;
&#xD;
        3. Other steroids daily regimen&#xD;
&#xD;
        4. Other steroids intermittent regimen. The study duration is planned for 19 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses&#xD;
      daily while the subject is in fed state, according to the child's weight.&#xD;
&#xD;
      Study drug should be permanently stopped if any of the following occur:&#xD;
&#xD;
        -  severe drug-related diarrhoea;&#xD;
&#xD;
        -  any drug-related Serious Adverse Event;&#xD;
&#xD;
        -  QTcF &gt;500 msec;&#xD;
&#xD;
        -  platelets count ≤50 x 10^9/L.&#xD;
&#xD;
        -  white blood cells ≤2.0 x 10^9/L&#xD;
&#xD;
        -  hemoglobin ≤8.0 g/dL&#xD;
&#xD;
      Study drug should be temporarily stopped if any of the following occur:&#xD;
&#xD;
        -  moderate or severe diarrhoea.&#xD;
&#xD;
        -  platelets count &lt;75 x 10^9/L but &gt;50 x 10^9/L (the treatment should be temporarily&#xD;
           stopped and a platelets count has to be performed and re-tested until platelets will be&#xD;
           normalized);&#xD;
&#xD;
        -  white blood cell &lt;3.0 x 10^9/L but &gt;2.0 x 10^9/L (the treatment should be temporarily&#xD;
           stopped and white blood cells have to be measured by 1 week and re-tested until white&#xD;
           blood cells will be normalized);&#xD;
&#xD;
        -  hemoglobin &lt;10.0 g/dL but &gt; 8.0 g/dL (the treatment should be temporarily stopped and&#xD;
           hemoglobin has to be measured by 1 week and re-tested until hemoglobin will be&#xD;
           normalized);&#xD;
&#xD;
        -  Triglycerides &gt;300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be&#xD;
           temporarily stopped and triglycerides has to be measured every 2 weeks until&#xD;
           triglycerides return to levels below 300mg/dL (3.42 mmol/L)&#xD;
&#xD;
      In case the study drug was temporarily stopped, the study drug can be resumed at a level 20%&#xD;
      smaller than the one at which the Adverse Event leading to temporary stop occurred, once&#xD;
      platelets and/or white blood cell and/or hemoglobin are normalized and/or triglycerides&#xD;
      return to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea is mild.&#xD;
&#xD;
      In addition, in case a subject will have a consistent (e.g., at least 2 consecutive&#xD;
      evaluations) platelets count ≤150 x 10^9/L and not meeting the stopping criteria for&#xD;
      platelets, the Investigator will have to reduce the dose by 20% of the current dose.&#xD;
&#xD;
      Only one dose reduction is allowed during the treatment period.&#xD;
&#xD;
      This trial design a single planned interim analysis. The interim will be governed by an IDMC&#xD;
      in order to solely assess futility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in 4 standard stairs climb</measure>
    <time_frame>18 months</time_frame>
    <description>the primary endpoint is the mean change in 4 standard stairs climb test results before and after 18 months of treatment of givinostat versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other functional test as 6MWT</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to rise from floor</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in time to rise from floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Spetroscopy</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in fat fraction of vastus lateralis muscles at MRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in North Star Ambulatory Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength evaluated by knee extension, elbow flexion</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change of muscle strength evaluated by knee extension, elbow flexion as measured by hand-held myometry (HHM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">179</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>givinostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Givinostat oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>givinostat</intervention_name>
    <description>suspension of givinostat (10 mg/mL)</description>
    <arm_group_label>givinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>suspension manufactured to mimic givinostat</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical&#xD;
             symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum&#xD;
             creatinine kinase level) already present at screening;&#xD;
&#xD;
          2. Have DMD diagnosis confirmed by genetic testing;&#xD;
&#xD;
          3. Are able to give informed assent and/or consent in writing signed by the subject&#xD;
             and/or parent/legal guardian (according to local regulations);&#xD;
&#xD;
          4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results&#xD;
             of these tests must be within ±1 second of each other;&#xD;
&#xD;
          5. Have the mean of 2 screening 4SC assessments ≤8 seconds;&#xD;
&#xD;
          6. Have time to rise from floor between ≥3 and &lt;10 seconds at screening&#xD;
&#xD;
          7. Have manual muscle testing (MMT) of quadriceps at screening Grade ≥- 3;&#xD;
&#xD;
          8. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the&#xD;
             start of study treatment, with no significant change in corticosteroids type or dosage&#xD;
             or dosing regimen (excluding changes related to body weight change) for a minimum of 6&#xD;
             months immediately prior to start of study treatment and a reasonable expectation that&#xD;
             dosage and dosing regimen will not change significantly for the duration of the study.&#xD;
&#xD;
          9. Subjects must be willing to use adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have exposure to another investigational drug within 3 months prior to the start of&#xD;
             study treatment;&#xD;
&#xD;
          2. Have exposure to idebenone within 3 months prior to the start of study treatment;&#xD;
&#xD;
          3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping)&#xD;
             within 6 months prior to the start of study treatment;&#xD;
&#xD;
          4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an&#xD;
             effect on muscle strength or function within 3 months prior to the start of study&#xD;
             treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will&#xD;
             be allowed as long as their intake has been stable for 3 months prior to the start of&#xD;
             study treatment; Testosterone will also be allowed if it is used as a replacement&#xD;
             therapy for the treatment of delayed puberty, and testosterone dose and regimen have&#xD;
             been stable for at least 6 months and circulating testosterone levels are within the&#xD;
             normal ranges for the subject's age;&#xD;
&#xD;
          5. Have surgery that might have an effect on muscle strength or function within 3 months&#xD;
             before study entry or planned surgery at any time during the study;&#xD;
&#xD;
          6. Loss of ≥30 degrees of plantar flexion from the normal range of movement at the ankle&#xD;
             joint due to contracture (i.e. fixed loss of more than 10 degrees of plantar flexion&#xD;
             from plantigrade, assuming normal range of dorsiflexion of 20 degrees;&#xD;
&#xD;
          7. Change in contracture treatment such as serial casting, contracture control devices,&#xD;
             night splints, stretching exercises (passive, active, self) within 3 months prior to&#xD;
             enrollment, or expected need for such intervention during the study;&#xD;
&#xD;
          8. Have presence of other clinically significant disease, which, in the Investigator's&#xD;
             opinion, could adversely affect the safety of the subject, making it unlikely that the&#xD;
             course of treatment or follow-up would be completed, or could impair the assessment of&#xD;
             study results;&#xD;
&#xD;
          9. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant&#xD;
             uncontrolled somatic disorders that are not related to DMD;&#xD;
&#xD;
         10. Have platelets count at screening &lt; Lower Limit of Normal (LLN);&#xD;
&#xD;
         11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class III&#xD;
             or IV) or left ventricular ejection fraction &lt;50% at screening;&#xD;
&#xD;
         12. Have a current or history of liver disease or impairment;&#xD;
&#xD;
         13. Have inadequate renal function, as defined by serum Cystatin C &gt;2 x the upper limit of&#xD;
             normal (ULN);&#xD;
&#xD;
         14. Have Triglycerides &gt; 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit;&#xD;
&#xD;
         15. Have a baseline QTcF &gt;450 msec, or history of additional risk factors for torsades de&#xD;
             pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);&#xD;
&#xD;
         16. Have a psychiatric illness/social situations rendering the potential subject unable to&#xD;
             understand and comply with the muscle function tests and/or with the study protocol&#xD;
             procedures;&#xD;
&#xD;
         17. Have any known allergic reaction to givinostat or any of its excipients.&#xD;
&#xD;
         18. Have any hypersensitivity to the components of study medication;&#xD;
&#xD;
         19. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of&#xD;
             fructose intolerance.&#xD;
&#xD;
         20. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or seizure&#xD;
             disorder).&#xD;
&#xD;
        At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria&#xD;
        may be re-screened twice with an interval of at least 3 months between assessments.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital center - UCSD Department of Neuroscience</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center - Division Neurology</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Health Research Institute - Department of Pediatrics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Department of Neurology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St Louis - Department of Neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia Colket Translational Research Building</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)</name>
      <address>
        <city>Liege</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of British Columbia, Children's and Womens Health Centre of BC Branch</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Uniersitat Munchen - Campus Innenstadt</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico NeMO Fondazione Serena ONLUS Area SUD</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario &quot;A.Gemelli&quot;, UOC Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>ZH 2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu - Neuromuscular Pathology Unit</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil - Passeig de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic de la Fe - Servicio Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD</name>
      <address>
        <city>London</city>
        <zip>EC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust</name>
      <address>
        <city>Oswestry</city>
        <zip>SY 10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

